Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently, he co-founded Elion Oncology which licensed PCS6422 to Processa. In addition, he founded Neurologic, an early-stage enterprise that in-licensed technology from the NIH for a diagnostic test for Alzheimer’s disease. He was also CEO at the North American subsidiary of Arpida Ltd., overseeing the organization of the phase 3 program for the NDA submission of an MRSA drug. And at Gentium, SpA, he led U.S. efforts to remediate the NDA for defibrotide. “Adding Mike to our leadership team will enable me to spend more time focusing on our long-term strategic direction and our pipeline,” Processa CEO and chairman David Young, MD, stated in the press release. “Mike is a proven life science entrepreneur with a demonstrated track record of successfully delivering results. He has the leadership capabilities we are looking for to help us grow Processa.”
To view the full press release, visit https://ibn.fm/InPvU
About Processa Pharmaceuticals Inc.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions, medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and Board of Directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit www.ProcessaPharmaceuticals.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
